Podcast
 |
| Jerry Flanagan, healthcare policy director for ConsumerWatchdog, discusses his group’s lawsuit against Anthem Blue Cross of California over its rate hikes, what they mean for healthcare reform, and why the proposed healthcare legislation wouldn’t have prevented Anthem from instituting the rate increases in the first place. |
G. Steven Burrill
Welcome from the CEO
Flash required to view this video. Download the latest version here
G. Steven BurrillNews
Biotech posts gain in February as broader markets strengthen March 03, 2010 | Press Release
Biotech holds steady in January as broader markets head south February 01, 2010 | Press Release
Biotech Closes the Year on an Upswing January 04, 2010 | Press Release
See all News
James D. Watson
Managing DirectorMr. Watson has broad therapeutic and drug discovery experience in strategy and partnership formation. Prior to joining Burrill & Company, he was a Senior VP with Incyte Genomics heading the Business Development and Marketing organizations. Before Incyte, he was General Manager and previously VP Business Development for Chemdex, a pioneering marketplace for research scientists with over 100 employees. Prior to Chemdex, Mr. Watson was Head of the San Francisco office of The Wilkerson Group where he built the office from 4 to over 30 consultants. Earlier, he gained operational experience with Lilly in Indianapolis and the UK in a variety of new product development and commercially focused roles. Mr. Watson received a Fulbright Scholarship and MBA from Indiana University and lectured in Economics at Portsmouth University, England.